- Exchange: NASDAQ CM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Exact Sciences Corp
+ Add to WatchlistEXAS:US
10.5600 USD 0.2600 2.40%As of 20:10:00 ET on 05/17/2013.
Snapshot for Exact Sciences Corp (EXAS)
| Open: | 10.8400 | Day's Range: | 10.4200 - 10.9200 | Volume: | 877,346 |
|---|---|---|---|---|---|
| Previous Close: | 10.5600 | 52wk Range: | 6.9300 - 12.3000 | 1-Yr Rtn: | +6.88% |
Key Statistics for EXAS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.8600 |
| Est. EPS (USD) (12/2013) | -0.7330 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 676.84 |
| Shares Outstanding (M) | 64.10 |
| 30 Day Average Volume | 2,269,737 |
| Price/Book (mrq) | 7.5935 |
| Price/Sale (ttm) | 155.7480 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/25/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for EXAS
Company Profile & Key Executives for EXAS
Exact Sciences Corp., is focused on developing and commercializing a non-invasive molecular screening test for the early detection and prevention of colorectal cancer. The Company's test is a stool-based DNA test that identifies both pre-cancer and cancer by detecting genetic mutations in colorectal cancer cells.
| Kevin T ConroyPresident/CEO | Maneesh K AroraSenior VP/CFO/COO |
| Graham P LidgardSenior VP/Chief Science Ofcr | Laura S StoltenbergSenior VP/Chief Intl Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
EXAS News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page